The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas

Micha Phill Grønholm Jepsen, Prajakta S Jogdand, Susheel K Singh, Meral Esen, Michael Christiansen, Saadou Issifou, Aurore B Hounkpatin, Ulysse Ateba-Ngoa, Peter G Kremsner, Morten H Dziegiel, Severin Olesen-Larsen, Søren Jepsen, Benjamin Mordmüller, Michael Theisen

64 Citationer (Scopus)

Abstract

GMZ2 is a hybrid protein consisting of the N-terminal region of the glutamate-rich protein fused in frame to the C-terminal region of merozoite surface protein 3 (MSP3). GMZ2 formulated in Al(OH)3 has been tested in 3 published phase 1 clinical trials. The GMZ2/alum formulation showed good safety, tolerability, and immunogenicity, but whether antibodies elicited by vaccination are functional is not known.
OriginalsprogEngelsk
TidsskriftThe Internet Journal of Infectious Diseases
Vol/bind208
Udgave nummer3
Sider (fra-til)479-88
Antal sider10
ISSN1528-8366
DOI
StatusUdgivet - 1 aug. 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas'. Sammen danner de et unikt fingeraftryk.

Citationsformater